Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib

Suzanne George, Quek
2010 Biologics : Targets & Therapy  
In the last decade a tremendous amount has been learned about the biology and treatment of gastrointestinal stromal tumor (GIST). Imatinib mesylate has revolutionized the treatment of metastatic GIST. In addition, the role of imatinib in localized GIST has gained much interest and may improve patient outcomes. Additionally, research efforts aimed at understanding the biology and the molecular heterogeneity of GIST both at initial presentation and at the time of resistance to imatinib, has
more » ... guide rational approaches to treatment as well as future efforts aimed at treating imatinib-resistant GIST. Prognostic factors As it became clearer investigators could reliably identify GIST, research efforts were focused on the determination of histological and clinical prognostic factors Biologics: Targets and Therapy downloaded from https: //www.dovepress.com/ by 207.241.231.82 on 24-Jul-2018 For personal use only.
doi:10.2147/btt.s4396 fatcat:cs6pxqztgvbcjamrsyjhxoqeqm